Roger was appointed CEO of Arcinova in September 2019, to further strengthen the executive management team as it continues its successful growth. Prior to taking up his position at Arcinova Roger spent six years establishing and developing a highly successful, industry led, biotechnology innovation centre hosted by the University of Strathclyde, as CEO of IBioIC. Other key roles have included General Manager of pharma service business in the USA and Managing Director of one of the largest controlled drug API manufacturers in the world.
With over 25 years of experience as an international business leader and a proven track record in business turnaround, growth and leadership. Roger’s background is in the biotechnology, chemical and fine chemicals sectors working for industry giants such as ICI and Johnson Matthey.
Roger is graduate of the University of South Wales with a first class degree in Chemical Engineering. He is a guest lecturer at Heriot Watt University and Chaired and sat on the boards of numerous Government, industrial, academic and learned institutions. He is a Fellow of the IChemE.
Arcinova, established in 2015 in the North East of England is one of the region’s fastest growing companies employing over 150 members of staff and offering a wide range of services that support nearly 200 clients in their drug development journeys. Arcinova’s services includes expertise in drug substance synthesis, manufacturing scale up, drug product manufacture, bioanalytical services and radiolabelling synthesis. Arcinova prides itself on combining agility with flexibility to provide an innovative approach to the development and manufacture of pharmaceutical products with a proven track record in saving our clients valuable time, enabling them to rapidly bring life-changing medicines to market.